<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057993</url>
  </required_header>
  <id_info>
    <org_study_id>NU 01B4</org_study_id>
    <secondary_id>NU-01B4</secondary_id>
    <secondary_id>PHARMACIA-NU-01B4</secondary_id>
    <nct_id>NCT00057993</nct_id>
  </id_info>
  <brief_title>Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer</brief_title>
  <official_title>Phase II Study Of Herceptin And Exemestane For Treatment Of Postmenopausal Women With Metastatic Hormone-Responsive, HER2/NEU Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2&#xD;
      on their surface and either kill them or deliver tumor-killing substances to them without&#xD;
      harming normal cells. Estrogen can stimulate the growth of breast cancer cells. Hormone&#xD;
      therapy using exemestane may fight breast cancer by reducing the production of estrogen.&#xD;
      Combining trastuzumab with exemestane may be an effective treatment for breast cancer with&#xD;
      high amounts of HER2.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab with exemestane&#xD;
      in treating postmenopausal women who have metastatic or locally advanced HER2-positive breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of exemestane and trastuzumab (Herceptin), in terms of response&#xD;
           rate and time to progression, in postmenopausal women with metastatic or locally&#xD;
           advanced hormone-responsive, HER2/neu positive breast cancer.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1 and oral exemestane&#xD;
      once daily. Treatment repeats every 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to accrue subjects to the study after 2 years - closed per request by Data Monitoring&#xD;
    Committee.&#xD;
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date>August 2004</completion_date>
  <primary_completion_date>August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Stage IV or locally advanced disease&#xD;
&#xD;
                    -  Staged by bone scan or CT scan of chest and/or abdomen within the past 6&#xD;
                       weeks&#xD;
&#xD;
          -  HER2/neu positive by fluorescent in situ hybridization (if 2+ by immunohistochemistry)&#xD;
             or 3+ by immunohistochemistry&#xD;
&#xD;
          -  Measurable disease defined by 1 of the following criteria:&#xD;
&#xD;
               -  At least 1 dimension at least 1 cm by CT scan or other imaging scan&#xD;
&#xD;
               -  At least 1 diameter at least 1 cm by plain x-ray (excluding bone lesions)&#xD;
&#xD;
               -  Palpable lesion with both diameters at least 1 cm with caliper OR&#xD;
&#xD;
          -  Evaluable disease defined by 1 of the following criteria:&#xD;
&#xD;
               -  Positive bone scan&#xD;
&#xD;
               -  Palpable masses with diameter less than 1 cm, masses with margins not clearly&#xD;
                  defined on CT scan or x-ray, or with both diameters less than 1 cm&#xD;
&#xD;
               -  Bone scan and CA 27.29 if bone scan only evaluable disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor and/or progesterone receptor positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal by 1 of the following criteria:&#xD;
&#xD;
               -  60 years of age and over&#xD;
&#xD;
               -  45 years of age and over with amenorrhea more than 12 months and an intact uterus&#xD;
&#xD;
               -  Follicle-stimulating hormone levels within postmenopausal range&#xD;
&#xD;
               -  Undergone bilateral oophorectomy&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction greater than 50%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior exemestane&#xD;
&#xD;
          -  No other prior hormonal agent (except tamoxifen)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia G. Kaklamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 23, 2011</disposition_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

